Page 14 - reflections_newsletter
P. 14
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #11 2026
The authors conclude that HDL-C might often be “guilty
by association” rather than a primary, direct driver of CLINICAL PEARLS FROM THE FACULTY Dyslipidaemia
atherosclerosis. Low or dysfunctional HDL-C frequently coexists
with systemic inflammatory and metabolic conditions, such as
obesity, diabetes, and tobacco use, which inherently heighten
CV risk. The medical community must undergo a paradigm shift.
Instead of viewing the sheer concentration of HDL-C as a direct
causal factor and therapeutic target, it should be recognised
primarily as a biomarker or risk enhancer, reflecting broader
metabolic dysfunction. Future interventions must prioritise
improving the actual functional capacity of HDL particles over
simply inflating their numbers.
WATCH
PROF. CRISTINA GAVINA DISCUSS
CLICK HERE THE CLINICAL RELEVANCE OF THIS
FOR THE LINK TO FULL ARTICLE ARTICLE.
ARTICLES OF INTEREST
REVIEWS AND PANELS
1. Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert
Panel (ILEP). Banach M, et al. Prog Cardiovasc Dis. 2025 Nov 16:S0033-0620(25)00166-5.
2. Biomarkers for cardiovascular drug development: JACC state-of-the-art review. Aimo A, et al. J Am Coll Cardiol. 2026
Feb 3:S0735-1097(25)10606-2. doi: 10.1016/j.jacc.2025.12.072. Online ahead of print.
3. Metabolic dysfunction-associated steatotic liver disease in adults: A review. Tilg H, et al. JAMA. 2026 Jan
13;335(2):163-174.
RISK PREDICTION AND SCREENING
4. Cascade screening for high lipoprotein(a): The time has come. Bittner V. Eur Heart J. 2025 Nov 19:ehaf830. doi:
10.1093/eurheartj/ehaf830. Online ahead of print.
5. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent
predictors of cardiovascular events. Markus MRP, et al. Eur Heart J. 2025 Oct 14;46(39):3863-3874.
6. Combining polygenic risk with LDL, CRP, and Lp(a) to predict coronary artery disease: UK biobank study. Khetarpal
SA, et al. J Am Coll Cardiol. 2025 Nov 25;86(21):2077-2080.
7. Risk-weighted apoB: A novel summary metric outperforming traditional lipid biomarkers in predicting coronary
heart disease. Rehman MB, et al. Eur Heart J. 2026 Jan 22:ehaf1124. doi: 10.1093/eurheartj/ehaf1124. Online ahead of
print.
TREATMENTS AND THERAPEUTICS
8. JCL Roundtable: Novel therapies in lipid management. Nissen SE, et al. J Clin Lipidol. 2025 Nov-Dec;19(6):1523-1529.
9. Not all fibrates are made equal: Learning from biology and clinical trials. Zambon A, et al. Atherosclerosis. 2025
Dec;411:120555.
TABLE OF CONTENTS
